Publications by authors named "Bo-Eric Persson"

Claim this Profile
D
Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials.
Peter Iversen, Jan-Erik Damber, Anders Malmberg, Bo-Eric Persson, Laurence Klotz

Ther Adv Urol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27).
Kurt Miller, Gabriele Simson, Sandra Goble, Bo-Eric Persson

Ther Adv Urol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Laurence Klotz, Kurt Miller, E David Crawford, Neal Shore, Bertrand Tombal, Bo-Eric Persson

Eur Urol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply by the authors.
E David Crawford, Bo-Eric Persson, Laurence Klotz

Urology· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026.
E David Crawford, Bo-Eric Persson

Eur Urol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.
E David Crawford, Neal D Shore, Judd W Moul, Bertrand Tombal, Fritz H Schröder, Bo-Eric Persson

Urology· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).
John Anderson, Ghandi Al-Ali, Manfred Wirth, Joan Benejam Gual, Francisco Gomez Veiga, Bo-Eric Persson

Urol Int· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607.
E David Crawford, Joel Eisner, Bo-Eric Persson

J Urol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: 'Use of androgen deprivation therapy in prostate cancer: indications and prevalence' by Connolly et al.
Bo-Eric Persson

Asian J Androl· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
Jan-Erik Damber, Teuvo L J Tammela, Peter Iversen, Per-Anders Abrahamsson, Laurent Boccon-Gibod, Bo-Eric Persson

Urology· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
E David Crawford, Bertrand Tombal, Kurt Miller, Laurent Boccon-Gibod, Fritz Schröder, Bo-Eric Persson

J Urol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.
Laurent Boccon-Gibod, Egbert van der Meulen, Bo-Eric Persson

Ther Adv Urol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.
Matthew R Smith, Laurence Klotz, Bo-Eric Persson, Tine Kold Olesen, Arthur A M Wilde

J Urol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
Fritz H Schröder, Bertrand Tombal, Kurt Miller, Laurent Boccon-Gibod, Neal D Shore, Bo-Eric Persson

BJU Int· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.
Bertrand Tombal, Kurt Miller, Laurent Boccon-Gibod, Fritz Schröder, Neal Shore, Bo-Eric Persson

Eur Urol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Degarelix: a new approach for the treatment of prostate cancer.
Bo-Eric Persson, Tine Kold Olesen, Jens-Kristian Jensen

Neuroendocrinology· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
Laurent Boccon-Gibod, Peter Iversen, Bo-Eric Persson

Expert Rev Anticancer Ther· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Will GnRH antagonists improve prostate cancer treatment?
Ilpo Huhtaniemi, Richard White, Craig A McArdle, Bo-Eric Persson

Trends Endocrinol Metab· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Laurence Klotz, Laurent Boccon-Gibod, Neal D Shore, Cal Andreou, Bo-Eric Persson

BJU Int· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
Marc Gittelman, Peter J Pommerville, Bo-Eric Persson, Jens-Kristian Jensen, Tine Kold Olesen

J Urol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer.
Hendrik Van Poppel, Bertrand Tombal, Jean J de la Rosette, Bo-Eric Persson, Jens-Kristian Jensen

Eur Urol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-84.
Philip Weston, Bo-Eric Persson

Eur Urol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
William A See, Manfred P Wirth, David G McLeod, Peter Iversen, Ira Klimberg, Bo-Eric Persson

J Urol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis